NMN vaidmens palaikant senstančių pelių storosios žarnos sveikatą suvokimas
Introductie
The gut is a diverse and dynamic microbiotic system. There are about 100 trillion microorganisms in the gut,kuris yramainly composed of anaerobic, partially anaerobic, and aerobic bacteria.In the process of ageing, the intestinal tract may show an increase in the permeability of the epithelial barrier and impaired tight junction proteins.Notably, supplementingβ-Nicotinamide mononucleotide(NMN) to elevateNAD+lygisHas been proved toprolong life andmaintain thecolonhealtasin ageing Mice.
Research protocol
Zmpste24−/− miceare frequently used in the construction of the prematurely ageing model, due to their features of slow weight gain, malnutrition and progressive hair loss, with a short median survival of about 20 weeks.Herein, to fathom out the role of NMN in maintaining the colon health of ageing mice, Zmpste24−/−mice aged 5-7 weeks are orally gavaged with phosphate-buffered saline (PBS), or NMN at 100/300 mg kg−1 every other day until natural death. Likewise, natural ageing C57BL/6 mice aged 10 months old are subjected to the oral gavage of PBS or NMN at300 mg kg−1, serving as the the control. During experiments, the body weight of mice is recorded, and their frailty index and fecal samples are detected.
The life span and frailty indices inZmpste24-/-mice after NMN treatment
NMN extends the healthy and median lifespan of Zmpste24−/−improves the Zmpste24−/− ageing phenotype. Specifically, the median lifespan of the mice is increased from 21.4 weeks to 25.7 weekspost NMN intervention, with more than 20% growth. Also, NMN effectively increases body weight. Meanwhile, mice have better overall health after NMN treatment, as manifested by the slowly increasing trend towards Sinclair's frailty indices.
The role of NMN in the intestinal tract of ageing mice
NMN adjuststhe activity of genes involved in ageing mice colons.Simply put,ašn the presence of NMN supplement,the protein level of transcriptional regulator P53 is reduced, while the expression levels of ageing marker Sirt1, NMNAT2 and NMNAT3 are elevated.
NMN improves the pathology of intestinal epithelial cells and intestinal permeability, as evidenced by the upregulation of intestinal tight junction protein (Claudin1,) and the number of goblet cells, the elevated release of anti-inflammatory factor (IL-10), and the increasing beneficial intestinal bacteria (Akkermansia muciniphilairBifidobacterium pseudolongum).
NMN improves the pathology of intestinal epithelial cells and intestinal permeability, as evidenced by the upregulation of intestinal tight junction protein (Claudin1,) and the number of goblet cells, the elevated release of anti-inflammatory factor (IL-10), and the increasing beneficial intestinal bacteria (Akkermansia muciniphilairBifidobacterium pseudolongum).
Išvada
NMNPapildųDaroa protective effect on colon mucosa by controlling the activity of genes involved in ageing, intestinal stem cell differentiation and improving intestinal flora homeostasis,which may be a viable strategy for maintaining healthy ageing in the gut.
Nuoroda
Yanrou Gu,Lidan Gao, Jiamin He et al.β-Nicotinamide mononucleotide supplementation prolongs the lifespan of prematurely aged mice and protects colon function in ageing mice.Food Funct., 2024 (15): 3199-3213.DOI: 10.1039/D3FO05221D
BONTAC NMN
BONTACYrathe pioneer ofNMNindustryand the first manufacturer to launch NMN mass production, with the first whole-enzyme catalysis technology around the world. At present, BONTAC has become the leading enterprise in niche areas of coenzyme products. Our services and products have been highly recognized by global partners. Furthermore, BONTAC has the first national and the only provincial independent coenzyme engineering technology research center in Guangdong, China. The coenzyme products of BOMNTAC are widely used in fields such as nutritional health, biomedicine, medical beauty, daily chemicals and green agriculture.
Atsakomybės apribojimas
Šis straipsnis pagrįstas nuoroda akademiniame žurnale. Atitinkama informacija pateikiama tik dalijimosi ir mokymosi tikslais ir nėra susijusi su jokiais medicininių patarimų tikslais. Jei yra kokių nors pažeidimų, susisiekite su autoriumi, kad jis būtų ištrintas. Šiame straipsnyje išreikštos nuomonės neatspindi BONTAC pozicijos.
Bontac jokiomis aplinkybėmis nebus laikoma atsakinga už jokias pretenzijas, žalą, nuostolius, išlaidas, sąnaudas ar įsipareigojimus (įskaitant, bet neapsiribojant, bet kokią tiesioginę ar netiesioginę žalą dėl pelno praradimo, verslo sutrikdymo ar informacijos praradimo), tiesiogiai ar netiesiogiai atsirandančius dėl jūsų pasitikėjimo šioje svetainėje pateikta informacija ir medžiaga.
Bontac jokiomis aplinkybėmis nebus laikoma atsakinga už jokias pretenzijas, žalą, nuostolius, išlaidas, sąnaudas ar įsipareigojimus (įskaitant, bet neapsiribojant, bet kokią tiesioginę ar netiesioginę žalą dėl pelno praradimo, verslo sutrikdymo ar informacijos praradimo), tiesiogiai ar netiesiogiai atsirandančius dėl jūsų pasitikėjimo šioje svetainėje pateikta informacija ir medžiaga.
